Latest Helus Pharma News & Updates

See the latest news and media coverage for Helus. We track all announcements, press releases, and industry mentions in real time, all in one place.

Helus Pharma (Helus)

Mental health biopharmaceutical company

helus.com

Headquarters: Toronto, Canada
Founded year: 2019
Company type: Public company
Number of employees: 100–200

Last updated Today

Latest news about Helus Pharma (Helus)

In short: Helus advanced its depression drug HLP003 into Phase 3 trials and secured $50 million in funding despite reporting a $148 million loss.

Company announcements

July 2 Helus

Helus discussed HLP003 Phase 3 program

CMO Dr. Amir Inamdar highlighted key considerations for adjunctive treatment in major depressive disorder.

June 29 Helus

Helus Pharma reports fiscal year 2026 financial results and business highlights

The clinical-stage company highlights Phase 3 enrollment progress and $50 million funding, while reporting a net loss of $148 million for the year.

June 25 Helus

Helus Pharma announces US$50 million underwritten offering

The offering of 10.3 million shares at US$4.85 each, led by Cantor and Barclays, closes on June 25, 2026.

June 24 Helus

Helus APPROACH Phase 3 trial enrollment surpasses 86%

The trial evaluates HLP003 for major depressive disorder with topline data expected in Q4 2026.

Media coverage

June 28 The Globe and Mail

HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

This news release constitutes a "designated news release" for the purpose of the Company's prospectus supplement dated December 30, 2025, to it short form base...

June 21 The Star

Helus Pharma Announces US$50 Million Underwritten Offering

NEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical stage...

June 21 Markets Insider

Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress

APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorder ("MDD") is progressing as planned and has...

April 24 Fierce Biotech

Chutes & Ladders—Helus shuffles out CEO after two months, adds experience to science board

Please send the good word—or ... or Zoey Becker and it will be featured here at the end of each week. Helus shuffles out CEO...

Never miss news about Helus

Track Helus and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Helus competitors & trending companies

Browse news for competitors to Helus and other trending companies.